MedTrace Logo

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

NCT04377503 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-29

No results posted yet for this study

Summary

This study compare the efficacy and safety of tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19

Conditions

Interventions

DRUG

Tocilizumab 180 MG/ML

Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.

DRUG

Methylprednisolone Sodium Succinate

Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use

Sponsors & Collaborators

  • Hospital Sao Domingos

    lead OTHER

Principal Investigators

  • PEDRO B FROTA, MD · Hospital Sao Domingos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-08-31
Completion
2020-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04377503 on ClinicalTrials.gov